Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
PaperCitations, authors & open-access status
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 88 citations, 2025 year and closed oa status.
88
Citations
2025
Year
closed
OA Status